Viral Clearance & Virus Filtration Patents: Who Leads 2026
Viral Clearance and Virus Filtration Patents: A Concentrated, Narrow Field
One assignee holds the entire ranking. all 14 records in scope trace to a single company, which is unusual concentration for a purification sub-field. Filings were flat at zero through the early coverage years, rose to a peak of 11 in 2021, then fell to zero by 2024 — a -100% change over that three-year span. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are still filling in and should not be read as confirmation that activity has ended.
- 1再生元制药公司100.0%
See the full viral clearance and virus filtration analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in viral clearance and virus filtration?
In this dataset, one company accounts for all 14 records in scope and the entire assignee ranking, including both of the most-cited filings on continuous virus retentive filtration. That degree of concentration is unusual and reflects how narrowly the search scope is defined around specific technical terms like log reduction value and spiking study, rather than a broad view of viral clearance patenting generally. A wider search string covering more general purification claims would likely surface additional filers.
Is patent filing in virus filtration increasing or slowing down?
Filing rose from zero in the early coverage years to a peak of 11 in 2021, then fell to zero by 2024, a -100% change over that three-year span. Because patent publication typically lags filing by around 18 months, the 2025-2026 figures in any dataset are still incomplete and should not be read as continued decline. The complete picture through 2024 shows a genuine pause after the 2021 peak, not merely a slowdown still being measured.
What does US20220106358A1 actually cover?
The filing describes a continuous processing system that connects a hydrophobic interaction chromatography (HIC) column inline with a virus retentive filtration (VRF) system built from at least two parallel filter trains. It targets viral clearance during antibody purification, addressing throughput and process-closure requirements as a combined step rather than as separate unit operations. Anyone designing a continuous purification line with inline VRF should review this claim scope carefully before finalising a similar architecture.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Viral Clearance and Virus Filtration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.